EUVIMEDEUVIMED entdecken
Crossref

Distortion product otoacoustic emission (DPOAE) reveals hearing loss up to 16 kHz in pediatric chemotherapy patients.

Dietmar Hecker, Marc K. H. Remke, Maximilian Linxweiler, Rhoikos Furtwängler, Yeliz Akrasu, Dominik Schöndorf, Norbert M. Graf, Dorothée Krieter, N Oberkircher, Bernhard Schick, Alessandro Bozzato, Arne Simon

Open Access CRIS of the University of Bern · 18.04.2026

DOI: 10.48620/97158 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Open Access CRIS of the University of Bern, erschienen am 18.04.2026. Verfasst von Dietmar Hecker und 11 weiteren Autor:innen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In pediatric cancer patients, platinum-induced sensory hearing loss (SHL) manifests in bilateral, symmetrical loss of outer hair cells and starts at a frequency range up to 10 kHz. Hearing loss has a significant impact on education, social integration and personality development in childhood cancer survivors. Early reliable detection of hearing loss may prompt attending oncologists to change chemotherapy if a less ototoxic therapeutic alternative is available. Pediatric cancer patients (2-19 years) receiving cisplatin-, carboplatin- or vincristine-containing regimens were eligible. Ultra-high frequency pure tone audiometry (PTA) and ultra-high frequency DPOAE measurements (up to 16 kHz) were compared. A total of 153 examinations were performed in 83 consecutive patients. While only 60 PTAs yielded reliable results, 153 DPOAE examinations up to 16 kHz were informative. Significant findings were observed between 10 and 16 kHz in both PTA and DPOAE assessments. In the cisplatin group, we found a significant reduction in DPOAE levels from 13 to 16 kHz, as well as a significant increase in DPOAE levels at 2.5 kHz and 3 kHz. Treatment with VCR and carboplatin did not result in substantial SHL. Hearing measurements up to 16 kHz can reveal an early ototoxic effect. In pediatric cancer patients, DPOAE measurement (up to 16 kHz) is more feasible and reliable (compared to PTA) and can detect SHL in ultra-high frequencies (10-16 kHz) at an earlier time point.

Schlagwörter

distortion product otoacoustic emissionsototoxicitycisplatincarboplatinvincristinechildhood cancerchemotherapy-induced hearing lossouter hair cellsearly detection of hearing loss

Zitieren

APA

Hecker, D., Remke, M. K. H., Linxweiler, M., Furtwängler, R., Akrasu, Y., Schöndorf, D., Graf, N. M., Krieter, D., Oberkircher, N., Schick, B., Bozzato, A., & Simon, A. (2026). Distortion product otoacoustic emission (DPOAE) reveals hearing loss up to 16 kHz in pediatric chemotherapy patients. Open Access CRIS of the University of Bern. https://doi.org/10.48620/97158

Vancouver

Hecker D, Remke MKH, Linxweiler M, Furtwängler R, Akrasu Y, Schöndorf D, et al. Distortion product otoacoustic emission (DPOAE) reveals hearing loss up to 16 kHz in pediatric chemotherapy patients. Open Access CRIS of the University of Bern. 2026. doi:10.48620/97158

BibTeX
@article{Hecker2026,
  author = {Hecker, Dietmar and Remke, Marc K. H. and Linxweiler, Maximilian and Furtwängler, Rhoikos and Akrasu, Yeliz and Schöndorf, Dominik and Graf, Norbert M. and Krieter, Dorothée and Oberkircher, N and Schick, Bernhard and Bozzato, Alessandro and Simon, Arne},
  title = {Distortion product otoacoustic emission (DPOAE) reveals hearing loss up to 16 kHz in pediatric chemotherapy patients},
  journal = {Open Access CRIS of the University of Bern},
  year = {2026},
  doi = {10.48620/97158}
}
Kostenlos starten →